Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect?
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect?

GeneDx Holdings Corp. (WGS) closed the last trading session at $80.47, gaining 24.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set

Why SJM Is a Top Pick for Income-Focused Investors in 2025
Why SJM Is a Top Pick for Income-Focused Investors in 2025

The J.M. Smucker Co. SJM has once again rewarded its shareholders by increasing its quarterly dividend from $1.08 to $1.10 per share — a 2% hike. This marks the company’s 24th consecutive fiscal

AAR Q4 Earnings Surpass Estimates, Sales Increase Year Over Year
AAR Q4 Earnings Surpass Estimates, Sales Increase Year Over Year

AAR Corp. (AIR) reported fourth-quarter fiscal 2025 adjusted earnings of $1.16 per share, which surpassed the Zacks Consensus Estimate of $1.00 by 16%. The bottom line also improved 31.8% from the

Here's Why AAR (AIR) is a Strong Momentum Stock
Here's Why AAR (AIR) is a Strong Momentum Stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service

Why Perrigo (PRGO) is a Top Momentum Stock for the Long-Term
Why Perrigo (PRGO) is a Top Momentum Stock for the Long-Term

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates

Here's Why Synchrony (SYF) is a Strong Momentum Stock
Here's Why Synchrony (SYF) is a Strong Momentum Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research

Here's Why PPL (PPL) is a Strong Momentum Stock
Here's Why PPL (PPL) is a Strong Momentum Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

PepsiCo (PEP) Q2 Earnings and Revenues Top Estimates
PepsiCo (PEP) Q2 Earnings and Revenues Top Estimates

PepsiCo (PEP) came out with quarterly earnings of $2.12 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $2.28 per share a year ago. These figures are

Here's Why Gen Digital (GEN) is a Strong Momentum Stock
Here's Why Gen Digital (GEN) is a Strong Momentum Stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research

Here's Why F5 Networks (FFIV) is a Strong Momentum Stock
Here's Why F5 Networks (FFIV) is a Strong Momentum Stock

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research

Here's Why Enbridge (ENB) is a Strong Momentum Stock
Here's Why Enbridge (ENB) is a Strong Momentum Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Is GE Vernova Thriving on Growing Nuclear SMR Opportunities?
Is GE Vernova Thriving on Growing Nuclear SMR Opportunities?

With increasing global demand for low-carbon energy sources, nuclear small modular reactors ("SMRs") are seeing increased adoption lately, thanks to their lower siting costs, shorter production

Should Investors Buy, Hold or Sell Costco Stock After June Sales?
Should Investors Buy, Hold or Sell Costco Stock After June Sales?

Costco Wholesale Corporation’s COST June sales results provide fresh insights into the retail giant’s performance. Known for its steady growth and leadership in the warehouse club space, Costco

Will Strong Travel Demand Support Hilton's RevPAR Growth in 2025?
Will Strong Travel Demand Support Hilton's RevPAR Growth in 2025?

Hilton Worldwide Holdings Inc. HLT entered 2025 with steady momentum, driven by a diversified travel demand base. In the first quarter, system-wide RevPAR grew 2.5% year over year, supported by

ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal

Zimmer Biomet Holdings ZBH recently entered into a definitive agreement to acquire Monogram Technologies Inc. MGRM, an orthopedic robotics company. Under the terms of the deal, ZBH will purchase all

Here's Why Reinsurance Group (RGA) is a Strong Growth Stock
Here's Why Reinsurance Group (RGA) is a Strong Growth Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Here's Why Zoetis (ZTS) is a Strong Growth Stock
Here's Why Zoetis (ZTS) is a Strong Growth Stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research

Why MPLX LP (MPLX) is a Top Growth Stock for the Long-Term
Why MPLX LP (MPLX) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates

Why Edison International (EIX) is a Top Growth Stock for the Long-Term
Why Edison International (EIX) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research

Why Acuity (AYI) is a Top Growth Stock for the Long-Term
Why Acuity (AYI) is a Top Growth Stock for the Long-Term

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas